Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“Breast Cancer Weekly Newsletter; My take from last week’s publications
1. Impact of Pathologic Response and Individual Prognosis After NAT in Patients with Early HER2+ and TNBC
The Breast
- pCR remains a powerful prognostic marker in HER2+ and TN disease, but among patients with RD, baseline clinical stage still matters and should inform post-neoadjuvant risk stratification.
2. Sacituzumab Govitecan in Patients with MBC: Pooled Safety Analysis of Data from Patients in North America, Europe, and Asia
ESMO Open
- Global pooled analysis shows that SG has a manageable safety profile across regions, while highlighting clinically relevant geographic and pharmacogenomic differences.
3. Preferences in CDK4/6 Inhibitors for ABC Among Medical Oncologists in Latin America JCO Global Oncology
- In Latin America, CDK4/6 inhibitor choice is not driven only by efficacy or toxicity, but also by structural access barriers.
4. Is NAC Justified When TNBC or HER2-Positive BC Presents as ≥1 cm of Only Calcifications or as a Subcentimeter Mass with Surrounding Calcifications?
Annals of Surgical Oncology
- When HER2-positive or TN disease presents mainly as calcifications without a clear mass, upfront surgery may be a more precise strategy than reflex neoadjuvant chemotherapy.
5. Impact of T-DXd and Brain SRS on Intracranial Control and Radionecrosis Risk in HER2-Positive or -Low BC Brain Metastases
The Breast
- These real-world data are reassuring: combining T-DXd with SRS does not appear to increase radionecrosis risk and may even improve intracranial control.
6. Tucatinib–Trastuzumab–Capecitabine for Treatment of Leptomeningeal Metastasis in Women with HER2+ BC: TBCRC049 Phase 2 Study Results
Nature Cancer
- TBCRC049 provides important prospective evidence that a fully systemic HER2-targeted regimen can deliver meaningful clinical benefit in leptomeningeal disease.
7. A Phase II Randomized Trial of Gemcitabine plus Cisplatin (GP) versus Gemcitabine plus Carboplatin (GC) as the First-Line Treatment of Patients with Metastatic TNBC
ESMO Open
- This trial does not establish cisplatin as superior to carboplatin in first-line metastatic TNBC, but it reinforces that platinum choice may be individualized according to toxicity profile.
8. DESTINY-Breast08: A Phase Ib Study of T-DXd in Combination with Other Anticancer Therapies in Patients with HER2-Low MBC
CCR
- T-DXd-based combinations in HER2-low MBC look feasible and active, particularly with endocrine therapy or capivasertib, but ILD surveillance remains essential as combination strategies move forward.
9. Landscape of Somatic Genetic Alterations and PAM50 Intrinsic Subtypes in Breast Cancer Associated with Germline Pathogenic Variants in DNA-repair Genes
JNCI
- Hereditary BC are not biologically uniform: germline DNA-repair gene status shapes both intrinsic subtype and somatic evolution, with potential implications for risk refinement and future therapeutic stratification.”
Other articles featuring Benjamin Walbaum on OncoDaily.
